Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
AstraZeneca (2)
56 Articles Available
2
3
Can't find what you're looking for? Try our
advanced search
.
Drug Approval
Farxiga Approved in the US for the Treatment of Heart Failure in Patients
PR-M05-20-NI-015
COVID-19 Vaccine
AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine
PR-M04-20-NI-042
Innovation
AstraZeneca-Singapore Establish Strategic Partnerships to Improve Health through Innovation
PR-M02-20-NI-015
Sustainability
AstraZeneca’s ‘Ambition Zero Carbon’ Strategy to Eliminate Emissions by 2025 and be Carbon Negative Across the Entire Value Chain by 2030
PR-M01-20-NI-035
Drug Approval
Calquence Approved in the US for Adult Patients with Chronic Lymphocytic Leukemia
PR-M11-19-NI-037
Drug Approval
Qtrilmet Approved in the EU for the Treatment of Type-2 Diabetes
PR-M11-19-NI-020
Approval
Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes
PR-M10-19-NI-029
FDA Priority Review
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
PR-M10-19-NI-025
Fast Track Designation
FDA Grants Fast Track Designation for Farxiga in Chronic Kidney Disease
PR-M08-19-NI-084
M&A
AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi
PR-M08-19-NI-083
Oncology
Imfinzi Improves Survival in the Phase III CASPIAN Trial in 1st-line Extensive-stage Small Cell Lung Cancer
PR-M07-19-NI-003
Agreement
UPMC Health Plan Announces Innovative, Value-Based Agreement with AstraZeneca
PR-M01-19-NI-084
Investment
Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2
PR-M01-19-NI-030
Leadership
AstraZeneca Announces Organizational Changes
PR-M01-19-NI-029
Drug Approval
AstraZeneca and FibroGen Receive First Approval for Anemia Drug in China
PAO-M12-18-NI-014
Influenza
FluMist Shipped by AstraZeneca
PAO-M10-18-NI-007
Approvals
Japan Approves Two New AstraZeneca Cancer Meds
PAO-M07-18-NI-001
Immunotherapy
India Gets First Immunotherapy for Lung Cancer
PAO-M06-18-NI-022
FDA Approval
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cance
PR-M04-18-NI-83
Vaccine
AstraZeneca Announces Renewed Recommendation and Availability of FLUMIST QUADRIVALENT Vaccine in the US
PR-M02-18-NI-96
Drug Development
Kidney Disease Drug Licensed to AstraZeneca
PAO-M02-18-NI-022
Immuno-Oncology
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
PR-M02-18-NI-020
Clinical Trials
COPD Patients Excited about AstraZeneca Trial Results
PAO-M02-18-NI-002
Ceremony
Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
PR-M01-18-NI-062
«
2
3
»
.svg)
